

April 1, 2025 full updates for the *Alberta Drug Benefit List (ADBL)*, *Alberta Human Services Drug Benefit Supplement (HSDBS)* and *Palliative Coverage Drug Benefit Supplement (PCDBS)*

Please be advised that the annual April 1, 2025 Full Updates to the *ADBL*, *HSDBS* and the *PCDBS*, including the Summary of Changes have been posted online at www.ab.bluecross.ca/dbl/publications.php

Drug products removed from the *ADBL* as the manufacturer *did not submit a price to the annual Alberta Price Confirmation (APC)*

As per the Alberta Price Policy, manufacturers with drug products currently listed on the *ADBL* were invited to re-quote the price of drug product(s) for continual listing. Please be advised that the following drug products will no longer be listed or eligible for payment under Alberta government-sponsored drug programs effective **April 1, 2025**, as these manufacturers have chosen not to confirm pricing.

All drug products scheduled to be removed from the *ADBL* have been identified as having therapeutic alternatives. Effective **April 1, 2025**, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A **30-day transition period** will be applied to allow physicians, pharmacists and patients directly affected by these changes sufficient time to transition to another drug therapy as appropriate and, as of **May 1, 2025**, claims will no longer pay for these products.

Patients impacted by the removal of these drug products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider(s).

DIN/NPN	Product description
00080062704	JAMP-POTASSIUM CHLORIDE ER 8 MEQ EXTENDED-RELEASE CAPSULE
00002367408	CLOXACILLIN 500 MG/VIAL INJECTION
00002367416	CLOXACILLIN 1 G/VIAL INJECTION

Drug products removed from the *ADBL* due to *discontinuation by the manufacturer*

The Alberta government-sponsored drug programs previously covered the following drug products; however, notification of discontinuation has been received from the manufacturers. Effective **April 1, 2025**, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A **30-day transition period** will apply and, as of **May 1, 2025**, claims will no longer pay for these products. Patients impacted by the discontinuation of these drug products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider(s).

continued next page

PHARMACY BENEFACT

continued from previous page

DIN	Product description
00002432463	LODALIS 3.75 G ORAL POWDER PACKET
00002489058	RIVA-DAPSONE 100 MG TABLET
00000657204	STIEVA-A 0.01% TOPICAL CREAM

For a summary of all updates, please refer to the Summary of Changes for highlights of products and pricing changes.

Please note that the online *interactive Drug Benefit List (iDBL)* is available at www.ab.bluecross.ca/dbl/idbl_main1.php; this is a near real-time application and as such, contains the most up-to-date information.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

